HOME › DRUGS › LACOSAMIDE
ACTIVE SUBSTANCE / INN

LACOSAMIDE

Brand name(s): Lacosamide Accord, LACOSAMIDE, MOTPOLY XR, VIMPAT, Lacosamide Adroiq, Lacosamide UCB, Vimpat, Lacosamide Pain UCB Pharma
FDA LISTED
EMA LISTED
DISCONTINUED
PRESCRIPTION
APPLICATION WITHDRAWN
Epilepsies, Partial
ANDA204787
ACTIVE SUBSTANCE
Lacosamide
REGULATORS
FDA · EMA
SPONSORS / MAH
Extrovis EU Ltd, UCB Pharma S.A., HETERO LABS LTD V
TOTAL APPLICATIONS
10
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
LACOSAMIDEANDA204787HETERO LABS LTD VPrescription
LACOSAMIDEANDA204855ACTAVIS LABS FL INCDiscontinued
LACOSAMIDEANDA204980GLENMARK PHARMS LTDNone (Tentative Approval)
VIMPATNDA022253UCB INCPrescription
MOTPOLY XRNDA216185AUCTAPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
VimpatUCB Pharma SAAuthorised29/08/2008Epilepsy
Lacosamide AdroiqExtrovis EU LtdAuthorised31/05/2023Epilepsy
Lacosamide AccordAccord Healthcare S.L.U.Authorised18/09/2017Epilepsy
Lacosamide UCBUCB Pharma S.A.Authorised26/08/2019Epilepsies, Partial
Lacosamide Pain UCB PharmaUCB Pharma S.A.Application withdrawnDiabetic Neuropathies

FULL INTELLIGENCE ON LACOSAMIDE

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →